The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung

被引:5
|
作者
Bulutay, Pinar [1 ]
Firat, Pinar [1 ]
Zeren, Handan [2 ]
Erus, Suat [3 ]
Tanju, Serhan [3 ]
Dilege, Sukru [3 ]
机构
[1] Koc Univ, Med Fac, Dept Pathol, Istanbul, Turkey
[2] Acibadem Univ, Med Fac, Dept Pathol, Istanbul, Turkey
[3] Koc Univ, Med Fac, Dept Thorac Surg, Istanbul, Turkey
关键词
PD-L1; lung cancer; immunotherapy; lung adenocarcinoma; IMMUNE CELLS; EXPRESSION; CANCER; IMMUNOHISTOCHEMISTRY; CLASSIFICATION; IMMUNOTHERAPY; RELIABILITY; ANTI-PD-1; LIGANDS;
D O I
10.3906/sag-2004-61
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: Programmed death ligand-1 (PD-L1) is a predictive marker for immunotherapeutic agents. However, heterogeneous staining of PD-L1 can cause false-negative results. The aim of this study is to evaluate the importance of histological patterns on PD-L1 staining heterogeneity in lung adenocarcinomas (LAC). Materials and methods: PD-L1 immunohistochemistry (IHC) stain was performed to two different tissue cores of 128 LAC cases, and cut-off values are given for grouping the cases according to the percentage of staining (1%-10%, 11%-49%, 50%-100%). Staining rates between cores were compared and analyzed by their histological patterns. Also, the relation of the PD-L1 expression with the clinicopathological characteristics of the cases was analyzed. Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off. PD-L1 expression was significantly related to the high grade micropapillary and solid patterns of adenocarcinomas (p:0.01). Staining cut-offs were mostly similar between cores (43/50, 86%) (k:0.843). However, 14% of them were positive only in one core (7 of 50). This false negativity was mostly related to the histological patterns. Conclusion: Our data reveal the heterogeneous staining of PD-L1 expression, also micropapillary and solid patterns show higher rates of PDL expression. Therewithal, these findings also highlight the importance of taking into consideration of histological patterns, when choosing a paraffin block for the PDL1.
引用
收藏
页码:204 / 213
页数:10
相关论文
共 50 条
  • [21] Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations
    Gagne, Andreanne
    Wang, Emily
    Bastien, Nathalie
    Orain, Michele
    Desmeules, Patrice
    Page, Sylvain
    Trahan, Sylvain
    Couture, Christian
    Joubert, David
    Joubert, Philippe
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : 2062 - 2070
  • [22] Time is up for PD-L1 testing standardization in lung cancer
    Dacic, S.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 791 - 792
  • [23] PD-L1 Expression in Lymphovascular Tumor Emboli in Lung Adenocarcinoma
    Yeh, Y.
    Ma, H.
    Ho, H.
    Chou, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S446 - S446
  • [24] The Clinical Utility of PD-L1 Testing in Selecting Non-Small Cell Lung Cancer Patients for PD1/PD-L1-Directed Therapy
    Villaruz, L. C.
    Socinski, M. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (03) : 212 - 214
  • [25] Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer
    Cagle, Philip T.
    Bernicker, Eric H.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (12) : 1477 - 1478
  • [26] Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors
    Del Re, Marzia
    van Schaik, Ron Hn
    Fogli, Stefano
    Mathijssen, Ron Hj
    Cucchiara, Federico
    Capuano, Annalisa
    Scavone, Cristina
    Jenster, Guido W.
    Danesi, Romano
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1875 (01):
  • [27] Understanding PD-L1 Testing in Breast Cancer: A Practical Approach
    Erber, Ramona
    Hartmann, Arndt
    BREAST CARE, 2020, 15 (05) : 481 - 490
  • [28] Development of IHC staining protocols for assessment of PD-L1 expression in cytological samples
    Boyiddle, Christine
    Ruboyianes, Mark
    Del Valle, Ed
    Bubendorf, Lukas
    Trunzer, Kerstin
    Pugh, Judith
    Boone, Jennifer
    CANCER RESEARCH, 2017, 77
  • [29] Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells
    Arrieta, O.
    Cruz-Rico, G.
    Aviles-Salas, A.
    Popa-Navarro, X.
    Flores-Velez, K. Y.
    Ramirez-Tirado, L.
    Vergara, E.
    Barron, F.
    Cabrera-Miranda, L. A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S162 - S162
  • [30] Comprehensive Assessment of PD-L1 Staining Heterogeneity and Expression by Histologic Pattern in Pulmonary Adenocarcinomas: Clinical Implications
    Gagne, Andreanne
    Enlow, William
    Pigeon, Marc-Antoine
    Orain, Michele
    Turcotte, Stephane
    Joubert, Philippe
    LABORATORY INVESTIGATION, 2017, 97 : 478A - 478A